About this Journal Submit a Manuscript Table of Contents
Case Reports in Radiology
Volume 2012 (2012), Article ID 236732, 5 pages
http://dx.doi.org/10.1155/2012/236732
Case Report

Celiac Artery Stenting to Facilitate Hepatic Yttrium-90 Radioembolization Therapy

Bridgeport Hospital, Yale New Haven Health System, 267 Grant Street, Bridgeport, CT 06610, USA

Received 2 October 2012; Accepted 6 November 2012

Academic Editors: E. Bölke, T. Chakera, A. Matsuno, and D. Tsetis

Copyright © 2012 Murthy R. Chamarthy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Radioembolization offers a novel way to treat the nonresectable, liver predominant hepatic malignancies with better tumor response and overall progression-free survival rates. Transarterial catheter-based radioembolization procedure involves the hepatic arterial administration of glass- or resin-based beta emitting Yttirum-90 microspheres. Safe delivery of the tumoricidal radiation dose requires careful angiogram planning and coil embolization to quantify lung shunting and prevent systemic toxicity, respectively. Diagnostic pretreatment angiogram also serves to identify the hepatic arterial variant anatomy and other coexisting pathologies that might require a different or alternative approach. We describe a complex case of celiac artery stenosis with tortuous pancreaticoduodenal arterial arcade precluding access to the right hepatic artery for performing radioembolization. Celiac artery stenting of the stenosis was performed to facilitate subsequent safe and successful Yttrium-90 microsphere radioembolization.

1. Introduction

A 74-year-old female with metastatic colorectal carcinoma to the right hepatic lobe (T4 N2 M1 at presentation) is status post colon and segment VI hepatic resection, and chemotherapy. She was referred for Yttrium-90 (90Y) radioembolization procedure for treatment of unresectable stable right hepatic lobe metastatic lesions (Figure 1). The liver and renal function tests and hematological indices were within normal range.

fig1
Figure 1: Contrast enhanced CT scan images demonstrate low attenuation right hepatic lobe lesions consistent with known metastatic disease (white arrows, (a) and (b)). Patient is status post partial segmental resection of the right hepatic lobe (black arrow, (c)).

2. Mapping and Treatment Angiograms

A planning or mapping angiogram was performed. The aortogram demonstrated a tight (approximately >90%) stenosis of the proximal celiac axis with mild poststenotic dilatation (Figure 2(a)). A superior mesenteric artery (SMA) angiogram demonstrated retrograde opacification of the hypertrophied pancreaticoduodenal arterial (PDA) arcade (Figure 2(b)). Despite using multiple microcatheter and guide wire combinations, catheterization of the right hepatic artery was unsuccessful given the extremely tortuous route precluding 90Y treatment. The only available remaining option for treatment was stenting of celiac artery to facilitate 90Y treatment. After appropriate discussion and consent, patient returned for additional mapping angiography, and a celiac artery stent was placed. Follow-up angiogram revealed widely patent celiac axis with no residual stenosis (Figure 3). Subsequently, coil embolization of the gastroduodenal artery (GDA) was performed via the stented celiac artery to prevent systemic radiotoxicity (Figure 3). Absence of abnormal extra hepatic radiotracer distribution and acceptable lung shunting was confirmed with intra-arterial administration of technetium-99m labeled macroaggregated albumin ( -MAA) within the right hepatic artery (Figure 4).

fig2
Figure 2: (a) Aortogram demonstrates a tight stenosis of the proximal celiac axis (white arrow) with mild poststenotic dilatation. In this case, the celiac artery stenosis was assumed to be related to atherosclerosis. The stenosis limits the access of the hepatic arterial branches for radioembolization purposes. Prior surgical clips related to partial right hepatic resection are noted (black arrow). (b) Superior mesenteric artery angiogram demonstrates significant hypertrophy and enlargement of the inferior pancreaticoduodenal arcade with opacification of gastroduodenal artery, and hepatic branches in a retrograde fashion (white arrows). There was a small collateral vessel which traveled from the superior mesenteric artery in a superior direction and opacified the very distal celiac axis and splenic artery (black arrow) likely representing the Arc of Buhler. (c) The right hepatic artery was not accessible through the tortuous pancreaticoduodenal collateral arcade (white arrow).
fig3
Figure 3: Treatment phase right hepatic angiogram images (a, b) demonstrate celiac artery stenting (6 × 15 mm Cordis chromium balloon expandable stent, white arrows) resulting in widely patent celiac axis with accessibility to the hepatic arteries. Coil embolization of gastroduodenal artery (two 10 mm × 10 cm tornado coils and two 8 mm × 4 cm coils, black arrows) prevents abnormal extrahepatic distribution. Additionally, a small accessory right hepatic branch was also coil embolized (two 3 × 2 mm platinum coils, white line arrows on (b)) to allow safer dose delivery and probable intrahepatic vascular flow redistribution [1, 2]. 90Y microspheres were injected within the right hepatic artery till end point without any immediate complications.
236732.fig.004
Figure 4: During the mapping angiogram phase, 5 mCi of technetium-99m labeled macroaggregated albumin was injected within the right hepatic artery to quantify the liver-lung shunt. The planar scintigraphic images demonstrate distribution of the radiotracer within the right lobe of the liver without any abnormal extrahepatic distribution. Regions of interest were drawn within the lungs and liver resulting in an estimated maximum lung shunting of 3%.

Approximately 27.8 mCi (1029 MBq) of 90Y microspheres (110% of calculated dose) was administered within the right hepatic artery through the stented celiac artery approach during the treatment phase utilizing the standard protocol till the end point. Bremsstrahlung images obtained after the 90Y radioembolization confirm proper delivery of microspheres to the targeted region without any abnormal extratumoral distribution (Figure 5). Patient tolerated the procedure without any immediate complications.

236732.fig.005
Figure 5: Posttherapy Bremsstrahlung image of the abdomen confirms proper delivery of microspheres to the targeted region of the right hepatic lobe (white arrow) without any abnormal extratumoral distribution. Safe and effective microsphere radioembolization with minimal to no radiotoxicity requires careful planning and preparation.

3. Discussion

Microsphere radioembolization therapy is currently approved for unresectable hepatic metastatic disease from colorectal cancer (SIR-Spheres, Sirtex Medical, Lane Cove, NSW, Australia) and unresectable hepatocellular carcinoma as a humanitarian device exemption (TheraSphere, MDS Nordion, Ottawa, ON, Canada) within the United States. 90Y microspheres are permanent biocompatible and non-biodegradable medical devices with a 90Y beta emitter within glass spheres or adsorbed onto resin spheres. Tumor cells receive the blood supply predominantly through the arterial system compared to the normal liver tissue which receives supply from the portal venous system. This preferential flow facilitates selective delivery of the radioactive microspheres to the tumor during transcatheter arterial therapies [1]. The selective and localized administration decreases the systemic toxicity and at the same time increases targeted delivery to tumor. Radioembolization provides the added benefit of beta radiation to adjacent tumor cells in the immediate vicinity [4]. Given these unique characteristics of the 90Y microsphere treatment, multiple studies reported improved tumor response and delayed time to progression compared to other treatment modalities [47].

The first step in the multidisciplinary approach is the planning or mapping angiogram phase that serves to confirm the normal or variant hepatic arterial anatomy and to coil embolize the GDA. Subsequently, Tc-99m MAA is injected to confirm lack of extrahepatic distribution and quantify the intrinsic tumoral lung shunting, which is used in conjunction with anatomical imaging volume and laboratory data for dose calculation. The treatment phase angiogram serves to reconfirm the arterial anatomy of the tumor, after which the 90Y microspheres are administered selectively up to the calculated dose or until flow stasis is achieved. A posttreatment Bremsstrahlung scan confirms dose delivery to tumor and absence of extrahepatic activity. These technical details and guidelines have been meticulously described previously [810]. Posttreatment complications are most often related to the abnormal systemic radioactive distribution and the systemic adverse effect profile has been proven to be superior compared to the traditional chemotherapy and radiation treatments [11, 12].

Arterial variants and abnormalities in the mesenteric and hepatic circulations might require alternate techniques for safe and effective radioembolization [13]. Celiac artery stenosis can result from atherosclerosis (as in the presented case), tumor invasion, localized inflammation, ligament compression, and rarely agenesis limiting the access to the hepatic branches through the celiac axis [14]. In these cases, the SMA usually provides a rich collateral supply predominantly through the PDA arcade, which can easily be utilized for selective access to the hepatic branches [8, 13, 15, 16]. An alternative approach would be celiac artery stenting that involves placement of a stent across the celiac stenosis with subsequent access to the hepatic artery branches. Celiac artery stenting was previously reported for treatment of variety of conditions including chemoembolization purposes [1720].

Up to date, there have been a few case reports demonstrating the utilization of the SMA-inferior PDA approach for 90Y microsphere therapy in cases of celiac artery stenosis [8, 13]. The conceptual considerations of celiac artery stenting for microsphere radioembolization have been described [13]. There are no reported studies comparing the advantages and disadvantages of the two approaches described above. The relative choice of the approach is based on technical accessibility and individual preference. The clinical efficacy might be similar given the similar mechanism of localized delivery of the radioembolic microspheres. The retrograde PDA arcade approach has a theoretical risk of inadvertent radioembolization due to variation of flow patterns and possible technical difficulty to access hepatic artery branches in extremely tortuous cases. However, when technically possible, this retrograde approach obviates the need for an additional angiogram and GDA coil embolization. In our case, the SMA-PDA approach was not technically feasible and therefore celiac artery stenting provided the only route for selective access to the hepatic arteries. To our knowledge, this is the first reported case of celiac artery stenting to facilitate 90Y radioembolization treatment in English literature.

4. Conclusion

90Y microspheres radioembolization offers a unique opportunity to treat nonresectable, liver predominant hepatic malignancies with good tumor response, and overall progression free survival rates. Hepatic arterial variants and abnormalities such as arterial stenosis might limit access to the hepatic arterial branches supplying the tumor, and therefore, require alternate approaches or additional minimally invasive endovascular interventions. We report the use of stenting procedure in a case of celiac artery stenosis to facilitate hepatic 90Y microsphere radioembolization. This technique can be performed as a first line approach or in cases where the hepatic branches are not technically accessible through the conventional SMA-PDA arcade approach. Although the use of celiac axis stenting for 90Y microspheres radioembolization has been successful in our case, this approach should be evaluated further in a larger study population.

Abbreviations

-MAA:Technetium-99m macroaggregated albumin
:Yttrium-90
GDA:Gastroduodenal artery
SMA:Superior mesenteric artery
PDA:Pancreaticoduodenal artery.

References

  1. N. Karunanithy, F. Gordon, M. Hodolic et al., “Embolization of hepatic arterial branches to simplify hepatic blood flow before yttrium 90 Radioembolization: a useful technique in the presence of challenging anatomy,” CardioVascular and Interventional Radiology, vol. 34, no. 2, pp. 287–294, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. M. H. Abdelmaksoud, J. D. Louie, N. Kothary, et al., “Consolidation of hepatic arterial inflow by embolization of variant hepatic arteries in preparation for yttrium-90 radioembolization,” Journal of Vascular and Interventional Radiology, vol. 22, no. 10, pp. 1364–1371, 2011.
  3. R. J. Lewandowski, J. F. Geschwind, E. Liapi, and R. Salem, “Transcatheter intraarterial therapies: rationale and overview,” Radiology, vol. 259, no. 3, pp. 641–657, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Salem, R. J. Lewandowski, L. Kulik et al., “Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma,” Gastroenterology, vol. 140, no. 2, pp. 497–507, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Kennedy, S. Nag, R. Salem et al., “Recommendations for radioembolization of hepatic malignancies using Yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium,” International Journal of Radiation Oncology Biology Physics, vol. 68, no. 1, pp. 13–23, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Kennedy, D. Coldwell, B. Sangro, H. Wasan, and R. Salem, “Integrating radioembolization (90Y microspheres) into current treatment options for liver tumors: introduction to the international working group report,” American Journal of Clinical Oncology, vol. 35, no. 1, pp. 81–90, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Murthy, R. Nunez, J. Szklaruk et al., “Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications,” Radiographics, vol. 25, pp. S41–S55, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. D. M. Liu, R. Salem, J. T. Bui et al., “Angiographic considerations in patients undergoing liver-directed therapy,” Journal of Vascular and Interventional Radiology, vol. 16, no. 7, pp. 911–935, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Salem, R. J. Lewandowski, K. T. Sato et al., “Technical aspects of radioembolization with 90Y microspheres,” Techniques in Vascular and Interventional Radiology, vol. 10, no. 1, pp. 12–29, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Kennedy, D. Coldwell, B. Sangro, H. Wasan, and R. Salem, “Radioembolization for the treatment of liver tumors: general principles,” American Journal of Clinical Oncology, vol. 35, no. 1, pp. 91–99, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Hilgard, M. Hamami, A. E. Fouly et al., “Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival,” Hepatology, vol. 52, no. 5, pp. 1741–1749, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Riaz, R. J. Lewandowski, L. M. Kulik et al., “Complications following radioembolization with Yttrium-90 microspheres: a comprehensive literature review,” Journal of Vascular and Interventional Radiology, vol. 20, no. 9, pp. 1121–1130, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. R. J. Lewandowski, K. T. Sato, B. Atassi et al., “Radioembolization with 90Y microspheres: angiographic and technical considerations,” CardioVascular and Interventional Radiology, vol. 30, no. 4, pp. 571–592, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. C. M. Park, J. W. Chung, H. B. Kim, S. J. Shin, and J. H. Park, “Celiac axis stenosis: incidence and etiologies in asymptomatic individuals,” Korean Journal of Radiology, vol. 2, no. 1, pp. 8–13, 2001. View at Scopus
  15. S. Y. Song, J. W. Chung, J. W. Kwon et al., “Collateral pathways in patients with celiac axis stenosis: angiographic-spiral CT correlation,” Radiographics, vol. 22, no. 4, pp. 881–893, 2002. View at Scopus
  16. M. Okazaki, H. Higashihara, H. Ono et al., “Chemoembolization for hepatocellular carcinoma via the inferior pancreaticoduodenal artery in patients with celiac artery stenosis,” Acta Radiologica, vol. 34, no. 1, pp. 20–25, 1993. View at Scopus
  17. O. Ikeda, Y. Tamura, Y. Nakasone, and Y. Yamashita, “Celiac artery stenosis/occlusion treated by interventional radiology,” European Journal of Radiology, vol. 71, no. 2, pp. 369–377, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. I. J. Finch, “Use of the Palmaz stent in ostial celiac artery stenosis,” Journal of Vascular and Interventional Radiology, vol. 3, no. 4, pp. 633–636, 1992. View at Scopus
  19. I. Gotsman and A. Verstandig, “Intravascular stent implantation of the celiac artery in the treatment of chronic mesenteric ischemia,” Journal of Clinical Gastroenterology, vol. 32, no. 2, pp. 164–166, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. J. W. Kwon, J. W. Chung, S. Y. Song et al., “Transcatheter arterial chemoembolization for hepatocellular carcinomas in patients with celiac axis occlusion,” Journal of Vascular and Interventional Radiology, vol. 13, no. 7, pp. 689–694, 2002. View at Scopus